R R

What Is Retevmo?

Retevmo is a prescription targeted cancer medication containing selpercatinib, a kinase inhibitor designed to block abnormal signaling involving the RET protein. It is approved for selected cancers with RET gene fusions or mutations, including certain lung cancers, thyroid cancers, and other advanced solid tumors. Retevmo is available as oral capsules and tablets, with administration instructions that depend on the formulation. Genetic testing helps identify patients whose tumors carry the relevant RET alteration. Retevmo can slow cancer growth in eligible patients but does not cure every RET-associated malignancy. Treatment requires monitoring for liver injury, blood pressure changes, heart rhythm abnormalities, and other adverse reactions.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Retevmo?

Retevmo is a prescription targeted cancer medication containing selpercatinib, a kinase inhibitor designed to block abnormal signaling involving the RET protein. It is approved for selected cancers with RET gene fusions or mutations, including certain lung cancers, thyroid cancers, and other advanced solid tumors. Retevmo is available as oral capsules and tablets, with administration instructions that depend on the formulation. Genetic testing helps identify patients whose tumors carry the relevant RET alteration. Retevmo can slow cancer growth in eligible patients but does not cure every RET-associated malignancy. Treatment requires monitoring for liver injury, blood pressure changes, heart rhythm abnormalities, and other adverse reactions.

read more about retevmo ...

Copy this HTML:

Copy HTML Copied!

How Does Retevmo Work?

Retevmo inhibits RET receptor tyrosine kinase activity. RET gene fusions and certain mutations can produce abnormal signaling that encourages cancer cells to grow and survive. Selpercatinib blocks this kinase activity, interfering with pathways involved in tumor proliferation. It also has activity against certain other kinases, which may contribute to treatment-related effects. Retevmo is considered targeted therapy because treatment eligibility depends on identifying a particular genetic alteration in the cancer. Its effects vary with tumor type, previous treatments, and resistance mechanisms. A tumor without an appropriate RET alteration is not eligible for Retevmo solely because it is advanced.

What Cancers Does Retevmo Treat?

Retevmo is approved for adults with locally advanced or metastatic non-small cell lung cancer containing a RET gene fusion. It also treats adults and children aged two years and older with advanced or metastatic medullary thyroid cancer carrying a RET mutation when systemic therapy is needed. Additional indications include certain advanced RET fusion-positive thyroid cancers that are refractory to radioactive iodine, when appropriate, and other locally advanced or metastatic RET fusion-positive solid tumors after prior systemic treatment or when no satisfactory alternatives exist. In July 2026, the FDA granted traditional approval for the broader RET fusion-positive solid tumor indication. Eligibility depends on appropriate genetic testing.

How Should Retevmo Be Taken?

Retevmo is taken orally according to the patient's age, body size, formulation, and clinical circumstances. For adults and adolescents aged 12 years and older weighing at least 50 kg, the recommended dose is 160 mg twice daily. Those weighing less than 50 kg generally receive 120 mg twice daily. Children aged two through 11 years use body surface area-based dosing, which can include twice-daily or three-times-daily schedules. Capsules and tablets have formulation-specific administration instructions. Doses may require adjustment for certain CYP3A inhibitors, liver impairment, or adverse effects. Patients should not double a missed dose and should follow the label's instructions regarding vomiting and timing.

What Are the Side Effects and Warnings of Retevmo?

Common adverse effects include diarrhea, dry mouth, fatigue, swelling, constipation, rash, and laboratory abnormalities. Serious risks include liver toxicity, elevated blood pressure, QT prolongation, bleeding, hypersensitivity, impaired wound healing, and interstitial lung disease or pneumonitis. Tumor lysis syndrome can occur in susceptible patients. Growth plate abnormalities have been observed in pediatric patients receiving RET inhibitors, requiring appropriate monitoring. Retevmo can also harm a developing fetus. Clinicians monitor liver tests, blood pressure, electrolytes, and cardiac risk factors during treatment. Severe shortness of breath, unusual bleeding, fainting, or yellowing of the skin requires prompt medical assessment.

Common Questions About Retevmo

Is Retevmo the same as selpercatinib?

Yes. Retevmo is the brand name for selpercatinib, a targeted kinase inhibitor used for selected cancers with RET gene alterations.

Can Retevmo treat lung cancer?

Yes. Retevmo is approved for adults with locally advanced or metastatic non-small cell lung cancer containing a RET gene fusion.

Can children receive Retevmo?

Yes. Retevmo is approved for certain RET-altered thyroid cancers and other advanced solid tumors in children aged two years and older, subject to the specific indication.

Does Retevmo require genetic testing?

Yes. Treatment eligibility depends on identifying an appropriate RET fusion or mutation using an FDA-approved test as specified in the prescribing information.

References

DailyMed - RETEVMO (selpercatinib) capsules and tablets. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828. Date Accessed November 3, 2026.

FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive. Date Accessed November 3, 2026.

Selpercatinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620036.html. Date Accessed November 3, 2026.

Selpercatinib. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/selpercatinib. Date Accessed November 3, 2026.

Selpercatinib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Selpercatinib. Date Accessed November 3, 2026.